Guatemala clinical trial coverage: insurance before the trial starts

Guatemala trial insurance under Agreement 206-2021 sections 11 and 43.8. The CRO, the broker, and the carrier are different roles.

Regulatory sources checked November 7, 2026. General sponsor guidance, not legal advice or an approval guarantee.

This page is about clinical-trial insurance for a study in Guatemala. It does not quote premiums, limits, or carrier rates. Confirm the current ethics, regulatory, import, and coverage rules with qualified advisers and a licensed broker.

What the current norm says

Ministerial Agreement 206-2021, section 11, requires insurance before a clinical trial begins. The policy has to cover the injury, disability, and death risks described in that section. Section 11.3 says the insurer is established in Guatemala or has an agreement with a national insurer, and that compensation for equal harm should match what the sponsor would pay in the country where the trial originated. None of these provisions sets a minimum dollar limit. Limits come from the contract and from underwriting.

For a device investigation, section 43.8 asks for a copy of the trial policy in the authorization file. The same insurance duty applies before the study starts. It is not a commercial-registration requirement and it is not a quote.

Acuerdo Ministerial 82-2019 is an earlier instrument that also addressed trial insurance. The rule sponsors should plan against now is the one in Agreement 206-2021, sections 11 and 43.8. This update does not say the older insurance duty was imaginary. It cites the norm that is current as checked on 7 November 2026.

Three different jobs

  • Carrier. Underwrites the participant-injury policy and decides whether to offer terms.
  • Broker. Places that policy with a carrier and explains the form, territory, and limits. A broker is not the sponsor and not the CRO.
  • CRO. Can help the sponsor assemble the ethics and regulatory file, including a policy copy where the dossier requires one. bioaccess® does not underwrite, bind, or quote coverage on this page. An introduction to a broker or carrier is not a partnership and not a binder.

A U.S. general-liability or product-liability policy covers a Guatemala trial only if the carrier confirms that the form actually includes the country and the investigational activity. Get that confirmation in writing.

This page does not say that bioaccess® is already running studies in Guatemala. Insurance planning is protocol-specific, like the rest of startup. Authorization timing is a different subject, described on clinical trials in Guatemala.

The multi-country explainer is clinical trial liability insurance in Latin America. This page stays on Guatemala.

Contact bioaccess® to request a Guatemala feasibility assessment. Bring the product description, development stage, preclinical evidence, proposed population, procedures, and follow-up.

Frequently asked questions

Does bioaccess® sell clinical trial insurance?

No. A carrier underwrites the policy. A broker can place it. A CRO is neither of those.

Which instrument should the ethics exhibit follow?

Plan against Agreement 206-2021, section 11, and include the policy copy in a device application under section 43.8. Confirm the wording with the broker and with local advisers before you file.

Does the norm publish a minimum premium or limit?

No. Section 11 describes who may insure and what the policy is for. It does not publish a price.

← Back to Blog · Contact bioaccess®